Buprenorphine for Cancer Pain

Phase 4 Unknown 50 enrolled Fox Chase Cancer Center

NaSingle-groupOpen-labelSupportive care

Summary

This study will evaluate patients on both buprenorphine and full agonist opioids (FAO) to assess for withdrawal symptoms. Patients will be evaluated by clinicians and using validated tools to assess for pain and withdrawal. At the same time, patients will use a CPM Rx application on their phone to track medication use.

Timeline

Start: 2022-08-10
Primary completion: 2024-10-10
Completion: 2024-10-10

Publications

Background Schmidt-Hansen M, Taubert M, Bromham N, Hilgart JS, Arnold S. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care. 2016 Sep;6(3):292-306. doi: 10.1136/bmjspcare-2015-000939. Epub 2015 Dec 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buprenorphine	Other / unclassified	—	—

Indications

No indication recorded.